Detalhe da pesquisa
1.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med
; 387(2): 132-147, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35660812
2.
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Haematologica
; 109(3): 777-786, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37731379
3.
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience.
Haematologica
; 2023 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855036
4.
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Am J Hematol
; 96(2): 226-233, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33125764
5.
Lenalidomide-based response-adapted therapy for older adults without high risk myeloma.
Br J Haematol
; 184(5): 735-743, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30548250
6.
Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.
Am J Hematol
; 94(7): 794-802, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31021005
7.
Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study.
Biol Blood Marrow Transplant
; 24(2): 400-405, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29032266
8.
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
Br J Haematol
; 180(2): 271-275, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29048105
9.
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.
Blood
; 127(21): 2561-8, 2016 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-26932802
10.
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.
J Natl Compr Canc Netw
; 16(1): 11-20, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29295877
11.
Case Report of IgM Multiple Myeloma: Diagnosing a Rare Hematologic Entity.
Cancer Control
; 25(1): 1073274817744448, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29318955
12.
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.
Lancet Oncol
; 18(1): 112-121, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27927582
13.
IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.
Haematologica
; 102(5): 948-957, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28104702
14.
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 15(2): 230-269, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28188192
15.
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Blood
; 123(10): 1461-9, 2014 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-24429336
16.
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.
J Natl Compr Canc Netw
; 14(4): 389-400, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27059188
17.
Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.
Biol Blood Marrow Transplant
; 21(6): 1074-82, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25805300
18.
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Cancer
; 121(20): 3622-30, 2015 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26149422
19.
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Blood
; 122(18): 3122-8, 2013 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24014245
20.
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
Blood
; 122(14): 2331-7, 2013 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-23950178